Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AbbVie's 2Q Revenue up 34% | Contract Pharma

What are you searching for?

Sign in
Financial News

AbbVie’s 2Q Revenue up 34%

New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
2Q Revenues: $13.9 billion (+34%)
2Q Earnings: $769 million (loss of $739 million 2Q20)
Comments: Global revenues from the Immunology portfolio were $6.1 billion, up 15% with U.S. Humira sales of $4.3 billion, an increase of 7% while International Humira sales were $811 million, down 6% due to biosimilar competition; Global Skyrizi sales reached $674 million, +>100% and Global Rinvoq revenues were $378 million, +>100%. Global revenues from the Hematologic Oncology portfolio were $1.8 billion, up 14%; Global Imbruvica sales were $1.4 billion, up 7%, with U.S. sales of $1.1 billion and International Profit Sharing of $282 million; Global Venclexta sales were $435 million, up 38%.Global revenues from the Neuroscience portfolio were $1.5 billion; Global Botox Therapeutic sales were $603 million, up 39%; Global Vraylar sales were $432 million, up 26%. Global sales from the Aesthetics portfolio were $1.4 billion; Global Botox Cosmetic sales were $584 million, +>100%.

Read Contract Pharma’s Top Companies Report on AbbVie.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters